Skip to main content
Clinical Trials/EUCTR2013-000389-12-GB
EUCTR2013-000389-12-GB
Active, not recruiting
Phase 1

ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): A Randomised Double-blind Placebo Controlled Trial - ANDREA-LD

Cardiff University0 sites22 target enrollmentJuly 29, 2013

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Cardiff University
Enrollment
22
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 29, 2013
End Date
June 30, 2016
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Eligibility Criteria

Inclusion Criteria

  • Participants will be: i. Adult (18 years or over). ii. Have a learning disability as judged by administrative classification (e.g. on practice learning disability register, in receipt of an annual learning disability health check, in receipt of learning disability services) and a score on the Adaptive Behaviour Scale that converts to an estimated IQ of 70 or below using the method described by Moss and Hogg (1997\). iii. Currently prescribed one of two anti\-psychotic drugs, haloperidol or risperidone, for treatment of challenging behaviour.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 310
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range 0

Exclusion Criteria

  • Other than the obverse of the inclusion criteria, participants will be excluded if: i. They have a current diagnosis of psychosis, ii. They have had a known recurrence of psychosis following previous drug reduction in the past 3 years, iii. The clinician responsible for their treatment judges for any other reason that the participation in a drug reduction programme may be counter\-indicated.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Not Applicable
Does Antipsychotic Dose Reduction in combination with Evidence-Based Intensive Recovery Treatment (EBIRT) Lead to Better Functional Recovery in First Episode Psychosis: A Randomised Controlled TrialFirst Episode PsychosisMental Health - Psychosis and personality disordersMental Health - SchizophreniaPublic Health - Health service research
ACTRN12617000870358Orygen, the National Centre of Excellence in Youth Mental Health44
Active, not recruiting
Not Applicable
Deprescribing of antipsychotics of patients with dementia in long term care - an intervention studyF03Unspecified dementia
DRKS00017831Medizinische Fakultät der TU München, Klinik und Poliklinik für Psychiatrie und Psychotherapie32
Active, not recruiting
Not Applicable
Seponering av antipsykotika og antidepressiva hos demente pasienter med APSD i sykehjem - en åpen studie.The included patients are all elderly people with dementia of Alzheimer or vascular type. Their dementia is moderate or severe and they all have Behavioral or Psychological Symptomes (BPSD).MedDRA version: 8.1Level: LLTClassification code 10057678Term: Vascular dementia
EUCTR2006-000287-84-NOSykehuset Innlandet HF24
Completed
Not Applicable
Anti-psychotic drug reduction in primary care for adults with learning disabilitiesearning disabilitiesMental and Behavioural DisordersDevelopmental disorder of scholastic skills, unspecified
ISRCTN38126962Cardiff University (UK)310
Recruiting
Phase 3
Withdrawing off-label antipsychotics in people with intellectual disabilities: why does it fail?
NL-OMON55806Erasmus MC, Universitair Medisch Centrum Rotterdam122